Elixirgen Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EXG-34217 for Treatment of ...
BALTIMORE, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on treating rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced …